
Annual report 2024
added 01-24-2026
AstraZeneca PLC Net Debt 2011-2026 | AZN
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt AstraZeneca PLC
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | 9.86 B | 10.5 B | 12.5 B | 12.2 B | 11.8 B | 8.83 B | 4.49 B | 1.18 B | 2.61 B | 1.76 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 12.5 B | 1.18 B | 7.58 B |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M | ||
|
Adagene
ADAG
|
-71 M | $ 2.62 | 28.82 % | $ 147 M | ||
|
GlaxoSmithKline plc
GSK
|
16.5 B | $ 48.98 | 0.68 % | $ 173 B | ||
|
Acorda Therapeutics
ACOR
|
114 M | - | -24.86 % | $ 820 K | ||
|
Alterity Therapeutics Limited
ATHE
|
-34.7 M | $ 3.51 | 7.34 % | $ 8.45 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | ||
|
Grifols, S.A.
GRFS
|
5.36 B | $ 9.25 | 1.49 % | $ 6.83 B | ||
|
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | ||
|
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | ||
|
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B | ||
|
Galapagos NV
GLPG
|
-1.29 B | $ 34.61 | 0.61 % | $ 2.69 B | ||
|
BioLineRx Ltd.
BLRX
|
-13.9 M | $ 3.1 | 4.49 % | $ 908 M | ||
|
Applied Molecular Transport
AMTI
|
-56.5 M | - | - | $ 10.1 M | ||
|
Zoetis
ZTS
|
3.28 B | $ 123.99 | -0.31 % | $ 56.3 B | ||
|
BioNTech SE
BNTX
|
-973 M | $ 116.27 | -1.86 % | $ 27.2 B | ||
|
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - | ||
|
Ascendis Pharma A/S
ASND
|
-195 M | $ 235.41 | 2.95 % | $ 5 B | ||
|
Burford Capital Limited
BUR
|
-135 M | $ 9.74 | -1.37 % | $ 1.55 B | ||
|
ARCA biopharma
ABIO
|
-60.6 M | - | 1052.0 % | $ 415 M | ||
|
Acasti Pharma
ACST
|
-27.4 M | - | 4.01 % | $ 150 M | ||
|
Arrowhead Pharmaceuticals
ARWR
|
-115 M | $ 67.49 | -3.02 % | $ 9.03 B | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-3.5 M | $ 4.51 | 8.41 % | $ 9.81 B | ||
|
Aeterna Zentaris
AEZS
|
-65.1 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | ||
|
Akouos
AKUS
|
-92.9 M | - | 0.23 % | $ 488 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
-119 M | - | -15.15 % | $ 60.3 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
469 M | $ 25.92 | -0.86 % | $ 1.26 B | ||
|
Amneal Pharmaceuticals
AMRX
|
2.28 B | $ 13.49 | -0.66 % | $ 4.17 B | ||
|
AIkido Pharma
AIKI
|
-1.04 M | - | 1.93 % | $ 17.4 M | ||
|
Albireo Pharma
ALBO
|
-239 M | - | -0.23 % | $ 916 M | ||
|
CureVac N.V.
CVAC
|
-783 M | - | - | $ 867 M | ||
|
Aptose Biosciences
APTO
|
-5.53 M | - | -45.71 % | $ 1.2 M | ||
|
Acer Therapeutics
ACER
|
-2.08 M | - | 2.71 % | $ 14 M | ||
|
Aravive
ARAV
|
-49.6 M | - | -13.39 % | $ 1.45 M | ||
|
Alpine Immune Sciences
ALPN
|
-63.9 M | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
-62.7 M | - | 4.14 % | $ 49.1 M | ||
|
Athira Pharma
ATHA
|
-47.2 M | - | - | $ 269 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-12 M | - | -11.43 % | $ 502 K | ||
|
AVROBIO
AVRO
|
-76.6 M | - | 1083.1 % | $ 745 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-657 K | - | - | $ 7.46 M | ||
|
Aytu BioScience
AYTU
|
-19.9 M | $ 2.66 | -1.85 % | $ 16.7 M | ||
|
Arena Pharmaceuticals
ARNA
|
-25.4 M | - | -6.81 % | $ 3.04 B | ||
|
Brickell Biotech
BBI
|
-29.7 M | - | -5.38 % | $ 6.06 M | ||
|
Athersys
ATHX
|
-27.6 M | - | 3.77 % | $ 22.4 M | ||
|
Avenue Therapeutics
ATXI
|
-3.13 K | - | -52.27 % | $ 4.45 M | ||
|
BeiGene, Ltd.
BGNE
|
-2.44 B | - | 0.49 % | $ 251 B | ||
|
Biogen
BIIB
|
4.01 B | $ 171.89 | -1.1 % | $ 25 B |